Abstract

Simple Summary Cancer patients receiving chemotherapy treatment are at high risk of contracting severe coronavirus disease 2019, which is associated high morbidity and mortality. Recent studies have shown that cancer patients elicit lower humoral and cellular immune responses to both inactivated vaccines and mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines. We report the results of assessing the humoral and cellular immune responses induced by the BNT162b2 vaccine booster among cancer patients receiving chemotherapy that had previously completed a primary immunization schedule with either inactivated (CoronaVac) or BNT162b2 SARS-CoV-2 vaccines. Our study demonstrated that booster vaccines elicit strong humoral and cellular responses among cancer patients receiving chemotherapy treatment, regardless of the type of vaccine used as a priming dose. No significant differences in immune response between cancer patients who were given two initial doses of either CoronaVac or BNT162b2 were detected. After adjustment for relevant covariates, the homologous regimen was associated with higher neutralizing antibody positivity and total antibody levels. Cancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8-12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.